FDA advisory panel set to review Daxas for COPD in April
This article was originally published in Scrip
Executive Summary
The US FDA's pulmonary-allergy drugs advisory committee has scheduled a meeting for April 7th to review Nycomed's once-daily oral phosphodiesterase-4 inhibitor for chronic obstructive pulmonary disease (COPD) treatment Daxas (roflumilast), which in the US is being developed and commercialised by Forest Laboratories. Forest acquired the US development, manufacturing and commercialisation rights in August 2009.